The Checkpoint Inhibitor Refractory Cancer Market is Expected to Witness Remarkable Growth During the Study Period (2018-30), Assesses DelveInsight

The increment in Checkpoint Inhibitor Refractory Cancer market size is due to high potency against cancer cells, increase in R&D activity, rise in the cases of types of cancers, where checkpoint inhibitors are in use, expected commercial success of upcoming therapies which are going to resolve the issue of primary resistance, along with a hike in the usage of approved Checkpoint Inhibitor therapies in the 7MM.

LAS VEGAS, June 1, 2022 /PRNewswire/ -- DelveInsight's Checkpoint Inhibitor Refractory Cancer Market Insights report covers a detailed comprehension of Checkpoint Inhibitor Refractory Cancer market size by treatment, epidemiology, emerging therapies, market share of the individual therapies, current market, historical and forecasted Checkpoint Inhibitor Refractory Cancer market size from 2018 to 2030 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).

Some of the salient features from the Checkpoint Inhibitor Refractory Cancer Market Report: 

• The Checkpoint Inhibitor Refractory Cancer market size in the 7MM was valued at USD 11.5 million in 2020 and is anticipated to grow for the study period (2018-2030).
• Key pharmaceutical Checkpoint Inhibitor Refractory Cancer companies such as Bristol-Myers Squibb, AstraZeneca, Merck, Genentech, Hoffmann-La Roche, Regeneron Pharmaceuticals, Merck KGaA, Pfizer, Janssen Research and Development, LLC, 4D pharma plc, 4SC AG, OncoSec Medical, Mirati Therapeutics, Ascentage Pharma Group, ENB Therapeutics, Inc, Exicure, Inc, Evelo Biosciences, Inc., Merck Sharp & Dohme Corp, Eisai, Kartos Therapeutics, Exelixis, ImmunityBio, BerGenBio, CatalYm, Checkmate Pharmaceuticals, IQVIA Biotech, Taiga, and others are reported to bring a significant shift in the Checkpoint Inhibitor Refractory Cancer market.
• The Checkpoint Inhibitor Refractory Cancer emerging therapies that are expected to launch in the forecast period include MRx0518, Domatinostat (4SC-202), Sitravatinib, Tavokinogene Telseplasmid in combination with Pembrolizumab, Bemcentinib (BGB324) in combination with Pembrolizumab, CMP-001 in combination with Nivolumab, CTL-002, TBX-3400, and several others.
• The increase in Checkpoint Inhibitor Refractory Cancer market size is a direct consequence of an increase in R&D activity, a rise in the cases of the type of cancers where checkpoint inhibitors are in use, and the expected commercial success of upcoming therapies which are going to resolve the issue of primary resistance, along with a hike in the usage of approved checkpoint inhibitor therapies in the 7MM.

For further information on Market Trends & Impact of Therapies, Download the Checkpoint Inhibitor Refractory Cancer Market sample @ Checkpoint Inhibitor Refractory Cancer Report Sample 

Checkpoint Inhibitor Refractory Cancer 

Immune Checkpoint Inhibitors are the drugs that block immune checkpoints. By blocking them, these drugs allow immune cells to respond more strongly to cancer. This prevents the "off" signal from being sent, allowing the T-cells to kill cancer cells. A wide range of cancer types can be treated using Checkpoint Inhibitors, for example, lung cancer (NSCLC, and SCLC), melanoma, breast cancers (triple-negative, metastatic breast cancer), Hodgkin lymphoma, Urothelial carcinoma, Renal cell cancer (RCC) and several others. Immune checkpoint inhibitors provide an edge over other generally used treatment therapies like chemotherapy, as they possess greater survival time and high potency against cancer cells.

Checkpoint Inhibitor Refractory Cancer Epidemiology Segmentation

The Checkpoint Inhibitor Refractory Cancer Market Report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:

• Total Incidence cases of cancer type (Bladder cancer, Cervical Cancer, Melanoma, Merkel Cell Carcinoma, NSCLC, RCC,  and others) where Checkpoint inhibitors are currently being used
• Total Checkpoint Inhibitor treated patient pool in each cancer type
• Total Checkpoint Inhibitor refractory cases in each cancer type

Know-how Checkpoint Inhibitor Refractory Cancer Epidemiological Trends shaping in 2030 for the 7MM by downloading @ Checkpoint Inhibitor Refractory Cancer Epidemiological Insights

Checkpoint Inhibitor Refractory Cancer Market Outlook

Contrary to traditional cancer therapies like chemotherapy, radiation therapy or targeted therapies, immunotherapy is the most recent treatment option for many cancer types. Unlike chemotherapy, which acts directly on cancerous tumors, immunotherapy like checkpoint inhibitors treats patients by acting on their immune system. Common checkpoints that these inhibitors affect are the PD-1/PD-L1 and CTLA-4 pathways. Many checkpoint inhibitors are FDA approved for specific cancers.

In 2014, Opdivo (nivolumab) and Keytruda (pembrolizumab) were FDA-approved for melanoma treatment. Later on, Opdivo and Keytruda received approval in multiple cancer types. Atezolizumab (Tecentriq) was approved in 2016, it is a checkpoint inhibitor that targets the PD-1/PD-L1 pathway; approved for subsets of patients with bladder cancer, breast cancer, liver cancer, lung cancer, and melanoma. Approved in 2017, Avelumab (Bavencio) is a checkpoint inhibitor that targets the PD-1/PD-L1 pathway; approved for subsets of patients with bladder cancer, kidney cancer, and Merkel cell carcinoma, a type of skin cancer.

At present, there are a decent number of combinational therapies under investigation for several Checkpoint-Inhibitor Refractory Cancers. The outlook for these treatments is promising directly increasing the growth of the Checkpoint Inhibitor Refractory Cancer Market. Various clinical trials for these therapies have been fairly positive in terms of safety and efficacy. The results of these studies encourage further investigation into multiple cancer types. Some of these upcoming potential Checkpoint Inhibitor Refractory Cancer treatment therapies include Mirati's Product Sitravatinib which is produced in collaboration with Bristol-Myers Squibb, it is a well-known multi-kinase inhibitor. A Phase II trial is being conducted by BerGenBio with Merck Sharp & Dohme for Bemcentinib (BGB324) in combination with Pembrolizumab in patients with advanced Non-small cell lung cancer.

Discover more about which therapy set to grab substantial Checkpoint Inhibitor Refractory Cancer market share @ Checkpoint Inhibitor Refractory Cancer Market Share 

Checkpoint Inhibitor Refractory Cancer Market Dynamics

The dynamics of the Checkpoint Inhibitor Refractory Cancer market are anticipated to change as companies across the globe are thoroughly working toward the development of new drug therapy options to treat a wide array of Checkpoint-Inhibitor Refractory Cancers leading to a direct increment in the size of Checkpoint Inhibitor Refractory Cancer market. In addition to that, factors such as these upcoming therapies having novel mechanisms, with increased cases of targeted cancer types, and also high potency against cancer cells, are expected to make a surge in the Checkpoint Inhibitor Refractory Cancer market.  The increase in Checkpoint Inhibitor Refractory Cancer market size is a direct consequence of an increase in R&D activity in the refractory cancer field, a rise in the cases of the type of cancers where checkpoint inhibitors are in use, and the expected commercial success of upcoming therapies which are going to resolve the issue of primary resistance, along with a hike in the usage of approved checkpoint inhibitor therapies in the 7MM. All these aspects combined together serve as major boosters in the Checkpoint Inhibitor Refractory Cancer market. At present there is a decent number of combinational therapies under investigation, so the current scenario also anticipates a positive shift in the Checkpoint-Inhibitor Refractory Cancer market for the forecast period.

On the contrary, there is a high cost of the treatment, unreported and undiagnosed cases, as well as side effects associated with checkpoint inhibitors that can serve as potential setbacks for the Checkpoint-Inhibitor Refractory Cancer market. Also, despite being a highly successful therapy choice, there are chances of developing resistance to check point inhibitors because some patients do not respond from the beginning (primary resistance; refractory) or stop responding over the time (acquired resistance; relapsed), so this factor at times might act as a drawback in the Checkpoint-Inhibitor Refractory Cancer market growth.

Know which Checkpoint Inhibitor Refractory Cancer therapy is expected to score the touchdown first @ Checkpoint Inhibitor Refractory Cancer Market Landscape and Forecast

Scope of the Checkpoint Inhibitor Refractory Cancer Market Report

• Study Period: 2018-30
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Checkpoint Inhibitor Refractory Cancer Companies: Bristol-Myers Squibb, AstraZeneca, Merck, Genentech, Hoffmann-La Roche, Regeneron Pharmaceuticals, Merck KGaA, Pfizer, Janssen Research and Development, LLC, 4D pharma plc, 4SC AG, OncoSec Medical, Mirati Therapeutics, Ascentage Pharma Group, ENB Therapeutics, Inc, Exicure, Inc, Evelo Biosciences, Inc., Merck Sharp & Dohme Corp, Eisai, Kartos Therapeutics, Exelixis, ImmunityBio, BerGenBio, CatalYm, Checkmate Pharmaceuticals, IQVIA Biotech, Taiga
• Key  Checkpoint Inhibitor Refractory Cancer Pipeline Therapies: MRx0518, Domatinostat (4SC-202), Sitravatinib, Tavokinogene Telseplasmid in combination with Pembrolizumab, Bemcentinib (BGB324) in combination with Pembrolizumab, CMP-001 in combination with Nivolumab, CTL-002, TBX-3400
• Therapeutic Assessment:  Checkpoint Inhibitor Refractory Cancer current marketed and emerging therapies
• Market Dynamics:  Checkpoint Inhibitor Refractory Cancer market drivers and barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Unmet Needs
• KOL's views
• Analyst's views
• Market Access and Reimbursement

Discover more about the future market share of Checkpoint Inhibitor Refractory Cancer treatment therapies @ Checkpoint Inhibitor Refractory Cancer Market Forecast

Get in touch with our Business executive @ Checkpoint Inhibitor Refractory Cancer Market Landscape Analysis 

Related Reports

Intratumoral Cancer Therapies Market

DelveInsight's 'Intratumoral Cancer Therapies Market Insights, Epidemiology and Market Forecast—2030' report delivers an in-depth understanding of the Intratumoral Cancer Therapies, market drivers, market barriers, unmet medical needs, and key companies involved like Amgen, Idera Pharmaceuticals, Philogen, Oncolys BioPharma, Highlight Therapeutics, Takara Bio, NanOlogy,  Istari Oncology, Moderna Therapeutics, Intensity Therapeutics, and several others.

Prostate Cancer Market 

DelveInsight's "Prostate Cancer Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of Prostate cancer, emerging drugs, and key companies involved like Bayer Health Care, Amgen, Janssen Pharmaceutical, Sanofi, AstraZeneca/ Merck Sharp & Dohme, Bristol-Myers Squibb, Novartis, Hoffmann-La Roche, Pfizer, Clovis Oncology, Regeneron Pharmaceuticals, Suzhou Kintor Pharmaceutical, Eli Lilly and Company, and others.

CAR-T Pipeline Insights

DelveInsight's, "CAR-T Pipeline Insights, 2021," report provides comprehensive insights about 250+ companies and 250+ pipeline drugs in the CAR-T pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products, key companies including, AbbVie Inc, Adaptimmune Therapeutics PLC, Amgen, Inc, Celgene, DiaCarta, Inc, Endocyte, Inc, F1 Oncology, Inc, Fate Therapeutics Inc, Gilead, Humanigen, Inc, Immune Therapeutics, Inc, Intrexon, Corp, Juno Therapeutics, Inc, Kite Pharma, Inc, Lion TCR Pte Ltd, MaxCyte, Inc, Mesoblast, Ltd. and others.

Cervical Cancer Market

DelveInsight's 'Cervical Cancer Market Insights, Epidemiology, and Market Forecast-2030' report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology, current treatment practices, emerging drugs like Cemiplimab, Durvalumab, Tisotumab vedotin, and key companies involved like Genentech/Roche, Iovance Biotherapeutics, Advaxis, Agenus, Akeso Biopharma, Altor BioScience, Amgen/Allergan, AstraZeneca, Avastin Biosimilars, and others

ER+/ HER2-VE Breast Cancer Pipeline

DelveInsight's, "ER+/ HER2-VE Breast Cancer - Pipeline Insight, 2021," report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in ER+/ HER2-VE Breast Cancer pipeline landscape. It covers the pipeline drug profiles, and key companies involved like  BeiGene, H3 Biomedicine, AstraZeneca, Olema Pharmaceuticals, CytomX Therapeutics, Roche, G1 Therapeutics, Sanofi, Jiangsu HengRui Medicine, and several others.

Immune Checkpoints Activators Market

"Immune Checkpoints Activators Competitive Landscape, Technology and Pipeline Analysis, 2020" report provides comprehensive insights on the therapeutic development for this mechanism of action. The objective of the report is to establish an understanding of the therapeutic competitive landscape for Immune Checkpoints Activators, including the pipeline products in this space, and key companies involved such as Nektar Therapeutics, Abbvie, Roche, and many others.

Hereditary Transthyretin Amyloidosis (hATTR) Market 

DelveInsight's 'Hereditary Transthyretin Amyloidosis (hATTR)- Competitive Landscape, Market Insights, Epidemiology and Market Forecast-2030' report delivers an in-depth understanding of the Hereditary Transthyretin Amyloidosis (hATTR), historical and forecasted epidemiology, current treatment practices, emerging drugs and key companies involved such as Takeda, CSL Behring, Pharming Group, BioCryst Pharmaceuticals, Ionis Pharmaceuticals, KalVista Pharmaceuticals, and others.

Prostate Cancer Market 

DelveInsight's "Prostate Cancer Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of Prostate cancer, historical and forecasted epidemiology, current treatment practices, and key companies involved like Bayer Health Care, Astellas Pharma, Amgen, Janssen Pharmaceutical, Sanofi, Orion Corporation, AstraZeneca, Janssen Research & Development, Eli Lilly and Company, eFFECTOR Therapeutics, and several others.

Non-Small Cell Lung Cancer (NSCLC) Market

DelveInsight's 'Non-Small Cell Lung Cancer (NSCLC) - Market Insights, Epidemiology and Market Forecast - 2030' report delivers an in-depth understanding of the Non-Small Cell Lung Cancer, historical and forecasted epidemiology current treatment practices, emerging drugs, and key companies involved like Novartis Pharmaceuticals, AbbVie, Janssen Pharmaceuticals, Xcovery, Eli Lilly and Company, Sanofi, Pfizer, and others.

Browse Through Our Blog Posts

LAG 3: A Promising Next Generation Cancer Immunotherapy

PD-1 and PDL-1 Immune Check Point Inhibitors: A Prodigious Revolution in Cancer Treatment

Most Promising Oncological Drugs Expected to Launch in 2022

Other Trending Healthcare Report

Ependymoma Market | Zollinger-Ellison Syndrome Market | Vaso-Occlusive Crisis Market | Typhoid Fever Market | Supraventricular Tachycardia Market | Spinocerebellar Ataxias Market | Spain Healthcare Outlook | Severe Psoriasis Market | Secondary Hyperparathyroidism Market | Rhino-Conjunctivitis Market | Retinal Vein Occlusion Market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. 

Connect With Us at LinkedIn | Facebook | Twitter

Contact Us
Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg